The AI-powered ProPicks strategy launched by Investing.com in November 2023 has delivered a cumulative return of 184.93%, outpacing the S&P 500 by 104.28 percentage points.
While major U.S. benchmarks diverged on Monday, with the NASDAQ declining 0.8% and the Dow Jones rising 0.3%, AI-selected value stocks continued to rally. Among the top performers, Haemonetics surged 26.72% in August and 98.75% since selection, while Merck & Co advanced 15.71% in August and 45.23% since its January 2026 identification.
Other notable gains included Everforth at 14.28% in August and 85.08% since selection, and TPG Inc with a 22.34% monthly gain and 30.47% since selection. International selections also posted strong returns, with Yubico AB gaining 40.98% in August and 109.58% since selection, and Atp Ticari Bilgisayar Ağı ve Elektrik rising 26.69% in August and 113.43% since selection.
Haemonetics reported first-quarter 2027 revenue of $339.4 million and earnings per share of $1.14, beating prior guidance of $1.10 versus $1.01 expected. Management raised full-year revenue growth expectations to a range of 5% to 8%, citing a new supply agreement with CSL Plasma. The stock trades at 56% of its 52-week high with a forward price-to-earnings ratio of 14.9x and a PEG ratio of 0.34. Analysts at Citi recently upgraded the stock to Buy with a $90 price target.
Merck & Co, identified by the AI model in January 2026, posted $16.61 billion in quarterly revenue and earnings per share of $2.28, beating estimates by nearly 10%. Full-year revenue guidance was raised to $67.3 billion, supported by strong demand for its cardiovascular drug Winrevair and oncology treatment Keytruda. The company trades at 13.9x earnings with a PEG ratio of 0.24 and a 3.2% dividend yield, backed by 10.4% dividend growth.
